This article, published in Morbidity and Mortality Weekly Report, summarizes the Advisory Committee on Immunization Practices review of post-marketing safety surveillance data on RotaTeq®, the rotavirus vaccine by Merck & Co., Inc. The data reveal that cases of intussusception reported since its introduction in early 2006 did not exceed the expected background rate.

Author(s): US Centers for Disease Control and Prevention

Published: 2007

Resource types: Newsletter/article

Diseases: Rotavirus

Topics: Vaccine safety; Disease/vaccine specific information

Regions: North America and Europe